The use of local hyperthermia to treat cancer of the internal organs has been limited by the difficulty of controlling delivery of heat and limiting the effects to the tumour, but this can be overcome by using laser light transmitted through thin flexible fibres. Laser energy was delivered to tumours through fibres inserted percutaneously through needles directly into the centre of the tumour area. Ultrasound scanning was used to locate the tumour, position the fibres correctly within the tumour, and monitor the development of thermal necrosis in real time during laser exposure and through the subsequent period of healing. Five patients were treated (one with a tumour of the breast, one with a subcutaneous secondary tumour, one with a recurrent pancreatic tumour, and two with secondary tumours in the liver). Tumour necrosis was found on ultrasonography or computed tomography in all, and there were no immediate or delayed complications. In one patient the size of the isolated secondary tumour in the liver had not increased over 10 months, and he subsequently showed no other evidence of residual cancer.
Introduction
Hyperthermia has for many years been investigated as a way of destroying diseased tissue. The temperatures reached during conventional treatment by hyperthermia induced by microwave or radiofrequency applicators (41-440C) 2 have been used in treating a variety of superficial and deep seated tumours, as has whole body hyperthermia3; varying degrees of remission have been achieved. These techniques, however, are not precise in their control of energy delivered to the tumour.
Interstitial treatment delivers treatment directly into the centre of the target lesion, minimising the effects on surrounding normal areas. Radioactive isotope grains have been placed through needles into tumours of the pancreas4 and liver.5 Interstitial hyperthermia induced by lasers by inserting the light conducting quartz fibre into the tumour was first described in 1983. 6 Experimental work showed that areas of thermal necrosis ofpredictable extent (up to 1 6 cm in diameter) could be produced in the livers of rats with verv low powers from a neodymium yttrium aluminium garnet (Nd YAG) laser (0 5-2 W). The lesions heal by fibrosis and regeneration.7 With ultrasound scanning the development of these thermal changes can be visualised in real time during laser irradiation, their resolution during healing followed, and the appearances matched with histological changes and the tissue temperatures reached. ' In this pilot clinical study we applied this technique to four types of tumour in five patients.
Method
The five patients were referred as no other treatment was considered appropriate or they had refused alternatives. All had given informed consent. All tumours were accessible for percutaneous insertion of a flexible fibre for delivery of laser energy. The nature of the lesion being treated was confirmed histologically. Sedation and analgesia (diazepam 5-10 mg, pethidine 50 mg intravenously) were given to the patients undergoing an intra-abdominal application together with prophylactic antibiotics (flucloxacillin 500 mg with added gentamicin 80 mg for the intra-abdominal applications). Local anaesthesia (1% plain lignocaine) was given at the site of needle insertion.
The laser fibres (0-2-0-4 mm core diameter) were sterilised in glutaraldehyde and rinsed with saline. Each fibre was inserted by passing it down a 0 9-1 2 mm needle, the tip of which had been placed at an appropriate point within the tumour under ultrasound control. Once in the correct position, the fibre tip was advanced 3-5 mm from the needle to be in direct contact with tissue. When several treatment points were used the distance between these was <1 5 cm, the (fig l(a) ). The initial biopsy had confirmed secondary adenocarcinoma, whereas the repeat biopsy showed only necrotic tissue. To maximise the chance of ablating the entire lesion the outer part of the tumour was treated at three sites (fig l(b) ). Two further treatments were carried out six and 10 months later as ultrasound scans suggested regrowth, but at 10 months after the original treatment he remained well, the lesion in his liver was no larger than it was originally, and he had no other evidence of residual cancer. Hartmann's operation for local recurrence, and five months after this ultrasonography showed a single secondary tumour in the liver (5 x 5 cm). Four needles were positioned under ultrasound guidance with -0-1-5 cm between the tips in a square (fig 4(a) ). The four output fibres of the coupler were fed down the needles, and laser treatment was applied. The needles and fibres were then drawn back 2 cm, the same spacing between the fibre tips confirmed, and the treatment repeated. Figure 4( seen on further ultrasonography and in biopsy specimens. Several treatments were required for each tumour, and injecting alcohol was often associated with considerable pain, whereas our patients did not report pain. These reports did not mention changes seen on ultrasound scans during or immediately after injection, which we found useful in laser treatment.
The most important advantage of the laser is its precision. It is unlikely that it will ever be possible to predict the extent of necrosis around a site at which absolute alcohol has been injected with an accuracy comparable to that already possible with the laser technique.
In conclusion, interstitial laser hyperthermia is feasible and seems to be safe. A multiple fibre system makes it feasible to treat tumours of clinically relevant size in the centre of solid organs. The real challenge for the future will be to develop diagnostic techniques that disclose exactly how far individual tumours extend in a wider range of organs (unlike the well defined tumours treated in this pilot study) and to establish the conditions of laser treatment that give complete tumour ablation with safe healing. This combination of technologies may be valuable for treating otherwise untreatable tumours in a range of solid organs and for the primary treatment of small neoplasms such as tumours of the prostate and adrenal glands.
We thank Mr R C G Russell, Mr P Hawley, Mr In scientific research negative results are often more difficult to interpret than positive ones, as was shown by a clinical trial in which the homoeopathic medicine Rhus toxicodendron 6x was compared with a placebo and fenoprofen in the treatment of osteoarthritis. The homoeopathic medicine was found to be ineffective whereas fenoprofen gave an improvement.' There were two interpretations: either the effects of homoeopathy are only a placebo effect-that is, a true negative -or the result was a false negative one because of flaws in the design. Another trial had previously suggested that homoeopathy was effective in rheumatoid arthritis.
We designed a trial to clarify these results by overcoming the methodological criticisms while retaining a rigorous design. The main problem in designing clinical trials of homoeopathy is that prescriptions are based on criteria such as the pattern of symptoms as well as the diagnosis. A clinical trial based solely on diagnosis is therefore inappropriate. In a pilot study we had shown that R toxicodenidron 6c was the most commonly indicated homoeopathic medicine for fibrositis in our patients, being indicated in 42%.
Patients, methods, and results
We used the diagnostic criteria of Yunus et al for fibrositis.' Only patients with this syndrome, in whom the homoeopathic medicine R toxicodendron 6c was positively indicated were entered into the study. Thirty patients meeting the admission criteria were recruited in the rheumatology clinic of this hospital. The clinical characteristics of the patients were similar to those of other reported series regarding age, sex distribution, duration of symptoms, modalities, and number of tender points. The trial was double blind, placebo controlled, and of crossover design. After entry there was no further contact between the homoeopathic doctor and the patient until the treatment was finished. The clinical metrologist dispensed the treatment and performed the assessments and analyses blind. Patients received active treatment and an identical placebo for one month each in random sequence. The dose was two tablets sucked three times daily.
The active preparation was R toxicodendron 6c (Boiron) prepared from a tincture of the leaves of poison oak diluted 1:99 in ethanol and then vigorously shaken. This process was repeated six times to give the 6c potency-a dilution of 102 of the tincture. This was then put up on 125 mg lactose tablets (2% volume per weight). Preparation was as specified in the French national pharmacopoeia. The placebo was identical lactose tablets to which only pharmaceutical ethanol had been added (2% volume per weight). Blind testing of the active and placebo preparations for a battery of drugs yielded negative results. Assessment comprised the number of tender spots, 10 cm visual analogue scales of pain and sleep, and overall assessment. Comparison was made between values at the end of active and placebo treatment periods.
The patients did better in all variables when they took active treatment rather than placebo. The number of tender spots was reduced by about a quarter (p<0005). We reduced subjective data to nominal measurements (worse or better). If the null hypothesis were correct the direction of change after placebo and active treatment would be randomly distributed. Analysis showed a significant difference in favour of the homoeopathic medicine (table). Overall assessment also showed a preference for the active treatment, which was not significant.
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